Table 4.
Characteristics of neoadjuvant therapy for esophageal cancer in patients who completed the protocol including surgery.
| Variable | Frequency | Percentage |
|---|---|---|
| Number of induction chemotherapy cycles | ||
| 1 | 1 | 3.1% |
| 3 | 1 | 3.1% |
| 4 | 8 | 25% |
| 5 | 18 | 56.3% |
| 6 | 2 | 6.3% |
| 7 | 1 | 3.1% |
| 10 | 1 | 3.1% |
| Number of concurrent CRT cycles | ||
| 0 | 1 | 3.1% |
| 1 | 3 | 9.4% |
| 2 | 5 | 15.6% |
| 3 | 21 | 65.6% |
| 4 | 2 | 6.3% |
| Induction chemotherapy delay | ||
| No delay | 28 | 87.5% |
| 7 days or less | 3 | 9.4% |
| 8-14 days | 1 | 3.1% |
| 15 days or more | 0 | 0% |
| CRT Delay | ||
| No delay | 32 | 100% |
| Delay | 0 | 0% |
CRT, chemoradiotherapy.